Whitehawk Therapeutics, Inc.
Company Stats
- Market Cap
- $214.4M
- as of Sep 30, 2026
- Shares Outstanding
- 57.0M
- Free Float
- 41.2%
Income Statement
- Revenue
- $7.1M
- Operating Income
- -$114.4M
- Net Income
- -$20.6M
- EBITDA
- -$114.3M
- Revenue Growth, 3Y
- -22.3%
- FCF Margin, 3Y Avg
- -622.7%
- FCF Margin, Worst Year
- -1371.4%
Cash Flow
- Free Cash Flow
- -$98.0M
- FCF Yield
- -45.7%
- Owner FCF Yield
- -50.3%
Balance Sheet
- Cash & Equivalents
- $37.6M
Returns & Capital
- SBC, 3Y Avg
- $10.9M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $7.1M | -$98.0M | -1371.4% |
| FY2024 | $26.0M | -$61.2M | -235.6% |
| FY2023 | $24.4M | -$63.6M | -261.3% |
| FY2022 | $15.2M | -$50.1M | -329.2% |
| FY2021 | $14.0M | -$22.5M | -160.5% |
Annual filing data through FY ended December 31, 2025; shares and float as of October 30, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges
Healthcare Earnings: Demand Surges, Costs Bite Back